A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting

Study Overview
=================
Brief Summary
-----------------
This is a prospective, non-interventional study conducted in CP-CML patients receiving dasatinib who are enrolled by a sample of hematologists in France.

Official Title
-----------------
Prospective Assessment of Dasatinib Management Among CP-CML Patients With Dasatinib Initiation in a Real Life Setting: DasaREALISE.

Conditions
-----------------
Chronic Myeloid Leukemia

Intervention / Treatment
-----------------
* Other: Non-Interventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged greater than or equal to 18 years Patients diagnosed with CP-CML Patients who started dasatinib within the last month before inclusion, or on the day of inclusion or within the month after inclusion Exclusion Criteria: Patients participating in an ongoing interventional trial Patients diagnosed with AP-CML (accelerated phase) or BP-CML (blast phase)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CP-CML participants initiating dasatinib<br> | Other: Non-Interventional<br>* Non-Interventional<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of CP-CML patients remaining on dasatinib treatment |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distribution of median age of CP-CML patients receiving dasatinib |  | 24 months | 
| Distribution of sex ratio of CP-CML patients receiving dasatinib |  | 24 months | 
| Distribution of concomitant treatment of CP-CML patients receiving dasatinib |  | 24 months | 
| Distribution of cardiovascular risk factors of CP-CML patients receiving dasatinib |  | 24 months | 
| Distribution of body mass index (BMI) of CP-CML patients receiving dasatinib |  | 24 months | 
| Distribution of comorbidities of CP-CML patients receiving dasatinib |  | 24 months | 
| Distribution of disease characteristics duration between diagnosis and drug initiation in CP-CML patients receiving dasatinib |  | 24 months | 
| Distribution disease characteristics of last known molecular response in CP-CML patients receiving dasatinib |  | 24 months | 
| SOKAL distribution of disease characteristics of CP-CML patients receiving dasatinib |  | 24 months | 
| Distribution of prior treatment(s) of CP-CML patients receiving dasatinib |  | 24 months | 
| Incidence of initiating dasatinib due to suboptimal response |  | 24 months | 
| Incidence of initiating dasatinib due to failure |  | 24 months | 
| Incidence of initiating dasatinib due to intolerance |  | 24 months | 
| Incidence of initiating dasatinib due to convenience |  | 24 months | 
| Incidence of initiating dasatinib due to physician decision |  | 24 months | 
| Incidence of AE's |  | 24 months | 
| Incidence of SAE's |  | 24 months | 
| Utilization of dasatinib |  | 24 months | 
| Incidence of complete molecular response (CMR) |  | Up to 24 months | 
| Incidence of major molecular response (MMR) |  | Up to 24 months |